DDInter1082 DDInter1315
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
Norgestrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pioglitazone
Norgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linaclotide
Norgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Norgestrel {u} may lead to a major life threatening interaction when taken with {v} Griseofulvin
Norgestrel {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Norgestrel may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Norgestrel may lead to a major life threatening interaction when taken with Griseofulvin
Norgestrel may lead to a major life threatening interaction when taken with Encorafenib